Pancreatic Neoplasms
📧 Sign up to get email alerts when something new happens for Pancreatic Neoplasms.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-12EMA Authorised: Lynparza (olaparib) — AstraZeneca AB
Olaparib (Lynparza) has been authorised by the EMA for multiple indications across ovarian, breast, pancreatic, and castration-resistant pro…
-
EMA approval · 2026-06-03EMA Authorised: Lynparza (olaparib) — AstraZeneca AB
Olaparib (Lynparza) has been authorised by the EMA for multiple neoplasms including ovarian, breast, pancreatic, and castration-resistant pr…
-
EMA approval · 2024-11-29EMA Authorised: Onivyde pegylated liposomal (previously Onivyde) (irinotecan anhydrous free-base) — Les Laboratoires Servier
The European Medicines Agency authorised a pegylated liposomal form of irinotecan (Onivyde) for pancreatic neoplasms, with Les Laboratoires …